Adaptive Biotechnologies Corp. (NASDAQ: ADPT) has begun the rollout of a virtual clinical study, ImmuneRACE with Microsoft Corp. (NASDAQ: MSFT) to measure the participants in select metropolitan areas within the U.S. impacted by the coronavirus pandemic. Data will be made available to public health officials, scholars and health industry to facilitate solutions to the pandemic. LabCorp. utilizing its Covance drug development business will manage collection of the blood samples and nose/throat swabs from participants in the safety of their own homes.
The partners will measure the presence of specialized cells of the immune system in the blood called T cells that identify disease early and proceed to the combat infection. Adaptive and Microsoft are mapping out and measure the immune response of T cells specific to certain diseases and are now applying their combined capabilities to COVID-19.
“We’ve spent the past decade learning how the adaptive immune system naturally detects and treats all disease, and we are well-positioned to apply our immune medicine platform specifically to COVID-19. We’re hopeful that we can contribute important information that will become part of an immune scan to help reopen society,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. “As many are sheltering in place wondering how they can help, we wanted to launch ImmuneRACE with Microsoft and give people an opportunity to participate. These efforts are complementary to many global initiatives underway to study the virus itself.”
“We are dedicated to being part of the solution against COVID-19,” said Peter Lee, corporate vice president, AI and Research, Microsoft. “Immune response data may augment what we have been learning to date to help determine who is at greater risk of developing more severe symptoms and may help with future containment efforts. Anyone who has been affected by COVID-19 holds key information that can help contain and manage the virus.”